Building AI-Ready Life Sciences Data Platforms: From Audit to Analytics

Description and use

<p>In September 2026, IQVIA called trusted data, responsible AI, and enterprise governance the new life-sciences operating model. The controversial takeaway: your AI model probably is not the bottleneck. Your evidence chain is. <strong>Life sciences data management</strong> now wins or loses on lineage, quality, access control, and reproducibility.</p> <h2> Life Sciences Data Management Is Now an AI Credibility Problem </h2> <p>The FDA's current AI direction makes the shift hard to ignore. Its drug-development guidance centers model credibility on a defined context of use, and FDA says CDER dr

Problem

<p>In September 2026, IQVIA called trusted data, responsible AI, and enterprise governance the new life-sciences operating model. The controversial takeaway: your AI model probably is not the bottleneck. Your evidence chain is. <strong>Life sciences data management</strong> now wins or loses on lineage, quality, access control, and reproducibility.</p> <h2> Life Sciences Data Management Is Now an AI Credibility Problem </h2> <p>The FDA's current AI direction makes the shift hard to ignore. Its drug-development guidance centers model credibility on a defined context of use, and FDA says CDER dr

Outcome

<p>In September 2026, IQVIA called trusted data, responsible AI, and enterprise governance the new life-sciences operating model. The controversial takeaway: your AI model probably is not the bottleneck. Your evidence chain is. <strong>Life sciences data management</strong> now wins or loses on lineage, quality, access control, and reproducibility.</p> <h2> Life Sciences Data Management Is Now an AI Credibility Problem </h2> <p>The FDA's current AI direction makes the shift hard to ignore. Its drug-development guidance centers model credibility on a defined context of use, and FDA says CDER dr

Evidence

Building AI-Ready Life Sciences Data Platforms: From Audit to Analytics

Source